An interventional study of rTMS and Sham in Fibromyalgia, Depression - Major Depressive Disorder and Chronic Pain, sponsored by Hospital Ambroise Paré Paris. Recruiting at 1 site in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-06-11.
Sponsored by Hospital Ambroise Paré Paris · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 49 studies in Fibromyalgia with a site in France — 4 open to participants now, 5 under way, none of them phase 3. Fibromyalgia · France.
Among the 49 studies in Fibromyalgia with a site in France, this one is the 41st largest by planned enrollment of the 46 interventional ones that give a count, is the only one that started in 2026, is one of 31 with no phase, and was the 48th registered.
1,245 studies on the registry are indexed under Fibromyalgia; 256 are open to participants now.
Browse Fibromyalgia studies →4 of the 49 studies in Fibromyalgia with a site in France are open now. Recruiting first, the newest first:
Institut De La Colonne Vertebrale Et Des Neurosciences · Sites in France
Ages 18–75
Nadine ATTAL · Sites in France
Ages 18–80
University Hospital, Montpellier · Sites in France
Ages 18+ · Healthy volunteers
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 161 Fibromyalgia studies recruiting now, 51 (32%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
49 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 36 is below the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 80 across the 46 interventional studies, 125 across the 3 observational. Of the 42 that completed or were terminated, 7 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 49 have an industry lead sponsor. The 10 most frequent:
Hospital Ambroise Paré Paris is the lead sponsor of 23 studies on the registry; 6 are open to participants now.
Hospital Ambroise Paré Paris has 2 studies filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
1 of the studies in Fibromyalgia with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06250491Nadine ATTALDeep rTMS (H-coil) for Neuropathic Pain or Fibromyalgia | 2027-01-30 |
Add it to your calendar (.ics) → With an account.
Among the 49 studies in Fibromyalgia with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Repetitive Transcranial Magnetic Stimulation (rTMS) of the motor cortex is a recognized analgesic technique for the treatment of fibromyalgia pain, which represents a largely unmet medical need. However, the effectiveness of motor cortex rTMS is inconsistent, being observed in only about 40% of patients and not always long-lasting. It has been previously shown that predictive factors for a lack of response to motor cortex rTMS include the presence of depressive symptoms, and that prefrontal cortex rTMS is not effective for pain, even though this treatment has proven efficacy in major depressive disorder.
The hypothesis is that targeting both the motor and prefrontal cortices with rTMS will yield a particularly beneficial effect in fibromyalgia patients presenting with comorbid depressive symptoms.
Given the absence of established biomarkers for predicting rTMS response, an additional aim will be to develop reliable indicators of rTMS efficacy, based on clinical phenotype and measurements of oscillatory patterns assessed by electroencephalogram (EEG) recordings.
This is a monocentric, randomized, double-blind, parallel-group, sham-controlled trial. After providing informed consent, patients will first undergo brain magnetic resonance imaging (MRI) to determine the exact position of the coil for rTMS neuronavigation.
Clinical and psychological outcomes - assessed using validated self-report questionnaires - as well as neurophysiological parameters - including resting-state brain oscillatory activity (EEG) and cortical excitability measures (TMS and electromyography) - will be recorded at three time points: (i) at inclusion, approximately one week before treatment initiation; (ii) after completion of the 5-day intensive stimulation phase; and (iii) at the follow-up visit, two weeks after the end of treatment.
Correlations between the analgesic effects of active or sham rTMS and changes in clinical and electrophysiological parameters will be evaluated.
The treatment consists of 5 daily sessions of high-frequency rTMS of the motor and prefrontal cortex (one 30-minute session per day delivering 3000 pulses). This will be followed by: one session per week for the following 3 weeks; one session every 15 days during the following month.
This results in a total of 10 sessions over approximately 2 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Each rTMS session for each cortical target will include 30 trains of pulses delivered at 10 Hz for 10 seconds (100 pulses per train), with a 20-second interval between each train, resulting in a total of 3,000 pulses per session. The total duration will be 15 to 20 minutes per target, and 30 to 40 minutes for both cortical targets combined. The stimulation intensity for the left motor cortex will be set at 80% of the resting motor threshold, defined as the minimal stimulation intensity that induces an electromyographic response of ≥50 µV in the first dorsal interosseous muscle of the hand, contralateral to the stimulated hemisphere, in at least 5 out of 10 trials. For stimulation of the left prefrontal cortex, we will use a stimulation intensity of 120% of the motor threshold, as is customary in psychiatry and as in our previous studies on analgesia (Attal et al., 2021).
Device: rTMS
To perform the rTMS, a figure-of-eight Cool-B65 A/P coil (MagVenture) will be used. This coil features a symmetrical design with two indistinguishable faces-one for active stimulation and the other for sham stimulation. The side used for each rTMS session will be determined by a personalized USB key for each patient, which will be connected to the rTMS device. The sound emitted during stimulation will be identical regardless of the side of the coil used. Finally, to further strengthen the treatment blinding for both the patient and the operator, the scalp-tapping sensation induced by active rTMS will be mimicked by low-intensity electrical stimulation applied to the head via surface electrodes. This electrical stimulation will be synchronized with the magnetic pulses during both active and sham stimulation sessions.
Device: Sham
The active protocol will include 5 daily stimulation sessions during the first week (D1-D5), followed by one session per week for 3 weeks (W2, W3, W4), then 2 sessions spaced 2 weeks apart (W6, W8), for a total of 10 stimulation sessions. Evaluation will continue until 2 weeks after the final stimulation, that is, at week 10 after the start of treatment.
The sham protocol will follow an identical session schedule. Participants will be randomized to either the active or sham group in a parallel-group design, meaning each participant will receive only one of the two treatments throughout the entire duration of the study.
Change in average pain intensity over 10 weeks (Brief Pain Inventory)
The primary outcome measure will be the mean change from baseline over the course of 10 weeks (group x time interaction) in average pain intensity from the Brief Pain Inventory (scored on a 0-10 NRS with 0 = no pain and 10 = maximal pain intensity). Baseline average pain intensity will be assessed at inclusion, and just before the first rTMS session (Day 1) and will correspond to the average of these two values. Pain intensity will be further assessed immediately before each rTMS session at Days 2, 3, 4, 5 then at weeks 2, 3, 4, 6, 8, and finally 2 weeks after the last rTMS session at week 10.
Time frame: From enrollment to Week 10.
Weekly pain, fatigue and sleep disturbances
Weekly average of daily patient-reported scores for pain intensity, fatigue, and sleep disturbance, recorded in a self-assessment diary completed throughout the study. Pain intensity and fatigue are each assessed on a numerical rating scale from 0 (no pain/no fatigue) to 10 (worst imaginable pain/worst imaginable fatigue), where higher scores indicate worse outcome. Sleep disturbance is assessed on a numerical rating scale from 0 (no interference) to 10 (completely disrupted sleep), where higher scores indicate worse outcome.
Time frame: At each visit from baseline to Week 10.
Immediate effect of rTMS on pain intensity
Pain intensity at the present moment assessed immediately after each rTMS session using a Numerical Rating Scale (NRS) ranging from 0 (no pain) to 10 (worst imaginable pain).
Time frame: At each visit from baseline to Week 10.
Onset of the therapeutic effect
The time to onset of the therapeutic effect from the first stimulation, assessed by measuring 24-hour pain scores recorded in the patient's self-assessment diary.
Time frame: At each visit from baseline to Week 10.
Brief Pain Inventory (BPI)
The validated French version of the BPI (Cleeland and Ryan, 1994) will be used to assess maximum and minimum pain over the past 24 hours and at the present moment, as well as the impact of pain (general activity, mood, ability to walk, usual work, relationships with others, sleep, quality of life), on numerical scales from 0 to 10.
Time frame: From enrollment to Week 10.
Fibromyalgia Impact Questionnaire (FIQ)
A validated self-report questionnaire specifically designed to assess the impact of fibromyalgia on quality of life. Scores range from 0 to 100, where higher scores indicate greater impact of fibromyalgia on functioning and worse outcome.
Time frame: At baseline, after 5 days of treatment, at weeks 4, 6, 8 and 10.
EuroQol 5-Dimension health status questionnaire (EQ-5D-5L)
A self-report questionnaire assessing health-related quality of life across 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each rated on a 5-level scale from 1 (no problems) to 5 (extreme problems), where higher scores indicate worse outcome. A Visual Analogue Scale (EQ-VAS) ranging from 0 (worst imaginable health) to 100 (best imaginable health) is also included, where higher scores indicate better outcome.
Time frame: At baseline, after 5 days of treatment, at weeks 4, 6, 8 and 10.
Hospital Anxiety and Depression Scale (HADS)
A self-report questionnaire assessing the severity of anxiety and depressive symptoms over the past week. It consists of two 7-item subscales - one for anxiety (HADS-A) and one for depression (HADS-D) - each scored from 0 to 21, where higher scores indicate greater symptom severity.
Time frame: At baseline, after 5 days of treatment, at weeks 4, 6, 8 and 10.
Patient Health Questionnaire (PHQ-9)
A validated 9-item self-report questionnaire assessing the presence and severity of depressive symptoms over the past two weeks. Total scores range from 0 to 27, where higher scores indicate greater severity of depressive symptoms.
Time frame: At baseline, after 5 days of treatment, and at Week 10.
Pain Catastrophizing Scale (PCS)
A 13-item self-report questionnaire assessing the tendency to magnify, ruminate, and feel helpless in response to pain. Each item is scored from 0 (not at all) to 4 (all the time), with a total score ranging from 0 to 52, where higher scores indicate greater catastrophizing.
Time frame: At baseline, after 5 days of treatment, at weeks 4, 6, 8 and 10.
Medical Outcome Study Sleep Scale (MOS)
A 12-item self-report questionnaire assessing the main dimensions of sleep quality, commonly used in chronic pain syndromes. Each item is rated on a 6-point categorical scale from 1 (all the time) to 6 (never). Scores are converted to a Sleep Problems Index ranging from 0 to 100, where higher scores indicate greater sleep disturbance.
Time frame: At baseline, after 5 days of treatment, at weeks 4, 6, 8 and 10.
Short-Form McGill Pain Questionnaire (SF-MPQ)
A 15-item self-report questionnaire assessing the sensory and affective dimensions of pain. Eleven items evaluate the sensory dimension and 4 items evaluate the affective dimension, each rated on a scale from 0 (none) to 3 (severe). Total scores range from 0 to 45, where higher scores indicate greater pain intensity.
Time frame: At the inclusion visit, baseline, after 5 days of treatment, at weeks 4, 6, 8 and 10.
Blinding Assessment Questionnaire
A validated questionnaire administered at the end of the study to assess the integrity of blinding. Participants are asked which treatment they believe they received (active, sham, or unsure) and the reasons for their belief (side effects, symptom relief, or other).
Time frame: At Week 10.
Patient and examiner's global clinical impression (PGIC, CGIC)
Single-item scales assessing the patient's and clinician's overall impression of change since the beginning of treatment, respectively. Both are rated on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse), where higher scores indicate worse outcome.
Time frame: From Week 2 to Week 10.
Credibility/expectancy questionnaire (CEQ)
A validated self-report questionnaire administered prior to treatment initiation to assess patients' beliefs about the credibility of the assigned treatment and their expectations regarding its therapeutic outcome. The first four items (Set 1), evaluating the cognitive dimensions of credibility and expectancy, will be used. Items are rated on a scale from 1 to 9, where higher scores indicate greater treatment credibility and expectancy.
Time frame: At baseline and after the first week of treatment.
Treatment responders
The percentage of treatment responders (patients whose pain is reduced by at least 30% and 50%) at the end of treatment.
Time frame: At Week 10.
Incidence of Treatment-Emergent Adverse Events
The safety and tolerability of the treatment, assessed by asking patients about any side effects experienced during the rTMS sessions.
Time frame: At each visit from baseline to Week 10.
Predictive value of baseline clinical variables on treatment response to active rTMS and sham
Assess the correlation between baseline clinical variables - including pain characteristics, demographic factors, and psychosocial factors - and treatment response to active rTMS and sham stimulation.
Time frame: From enrollment to Week 10.
Predictive value of baseline intracortical excitability and inhibition parameters assessed with TMS on treatment response to active rTMS and sham
Identify the correlation between motor cortical excitability and inhibition - assessed via motor evoked potentials (recorded from the first dorsal interosseous muscle of the hand) elicited by paired-pulse TMS - and treatment response to active rTMS and sham stimulation.
Time frame: From enrollment to Week 10.
Predictive value of baseline cortical oscillatory EEG biomarkers on treatment response to active rTMS and sham
Identify the correlation between baseline cortical oscillatory patterns extracted from resting-state EEG recordings and treatment response to active rTMS and sham stimulation. EEG recordings will consist of a 5-minute eyes-open and a 5-minute eyes-closed session using a 32-channel cap.
Time frame: From enrollment to Week 10.
Plan to share: Undecided — The plan to share individual participant data has not yet been determined.
Start is estimated for Sep 2026; primary completion for Nov 2028, 26 months later.
Of 439 non-industry interventional studies with no phase under Fibromyalgia, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 31. This study's planned 26 months is above that.
Counting every sponsor, half of 452 studies reached it within 15 months; a quarter within 6 and three quarters within 31.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Ambroise Paré Paris